← Back to Patent Explorer
US6077987A Expired / Lapsed US ⏱️ 0.0 years remaining

Genetic engineering of cells to enhance healing and tissue regeneration

Assignee: The Feinstein Institutes for Medical Research
•
Filing: 1997-09-04
•
Granted: 2000-06-20
•
Expires: 2017-09-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for enhancing and/or increasing the efficiency of repair of tissues, primarily bone or cartilage, using genetically engineered cells has been developed. In the preferred embodiment, mesenchymal stem cells are isolated from periosteum tissue, and transfected with the gene encoding a growth factor for the particular cell type to be repaired. For example, for repair of bone, a gene (or genes) encoding bone morphogenic protein is transfected into periosteal cells. The transfected periosteal cells then express the bone morphogenic protein in culture to promote bone repair as a function of the expressed bone morphogenic protein. Cells can be transfected using any appropriate means, including viral vectors, as shown by the example, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of DNA. Genes can encode any useful protein, for example, a specific growth factor, morphogenesis factor, a structural protein, or a cytokine which enhances the temporal sequence of wound repair, alters the rate of proliferation, increases the metabolic synthesis of extracellular matrix proteins, or directs phenotypic expression in endogenous cell populations. Representative genes encoding proteins include bone growth factor genes, cartilage growth factor genes, nerve growth factor genes, and general growth factors important in wound healing, such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1), epidermal growth factor (EGF), basic fibroblast growth factor (FGF), endothelial derived growth supplement.

Inventors

  • 👤 Arnold S. Breitbart
  • 👤 Daniel S. Grande
  • 👤 James M. Mason

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 12:10
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1875; A61K48/00

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 94 words
A method to modify wound healing, cell proliferation or differentiation in a patient comprising implanting at a site in a patient isolated cells genetically engineered in vitro to express bioactive molecules selected from the group consisting of bone growth factors, cartilage growth factors, nerve growth factors, and general growth factors important in wound healing and tissue repair in an amount effective to enhance the temporal sequence of wound repair, to alter the rate of cell proliferation, to increase the metabolic synthesis of extracellular matrix proteins, or to direct phenotypic expression in endogenous cell populations.
Claim 2
Independent Claim 94 words
A method to modify wound healing, cell proliferation or differentiation in a patient comprising implanting at a site in a patient isolated cells genetically engineered in vitro to express bioactive molecules selected from the group consisting of bone growth factors, cartilage growth factors, nerve growth factors, and general growth factors important in wound healing and tissue repair in an amount effective to enhance the temporal sequence of wound repair, to alter the rate of cell proliferation, to increase the metabolic synthesis of extracellular matrix proteins, or to direct phenotypic expression in endogenous cell populations.
Claim 3
Dependent Claim 11 words
The method of claim 1 wherein the cells are mesenchymal cells.
Claim 4
Dependent Claim 13 words
The method of claim 1 wherein the cells are isolated from periosteal tissue.
Claim 5
Dependent Claim 38 words
The method of claim 1 where the endogenous cells are cartilage forming cells wherein the bioactive molecules are selected from the group consisting of cartilage growth factors, and general growth factors important in wound healing and tissue repair.
Claim 6
Dependent Claim 64 words
The method of claim 1 wherein the growth factors are selected from the group consisting of platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), basic fibroblast growth factor (FGF), insulin-like growth factor (IGF), endothelial derived growth supplement (EDGS), keratinocyte growth factor (KGF), osteogenin, skeletal growth factor (SGF), osteoblast-derived(BDGFs), retinoids, growth hormone (GH), bone morphogenic proteins (BMPs), CBFA-1 and transferrin.
Claim 7
Dependent Claim 30 words
The method of claim 5 wherein the bioactive molecules are selected from the group of TGF-beta superfamily proteins consisting of bone morphogenic proteins (BMP), TGF-beta, and insulin-like growth factor (IGF).
Claim 8
Dependent Claim 26 words
The method of claim 1 wherein the cells are genetically engineered in vitro, then implanted at a site where tissue is to be formed or repaired.
Claim 9
Dependent Claim 27 words
The method of claim 1 wherein the cells are fibroblasts or chondrocytes genetically engineered in vitro, then implanted as part of a prosthetic for repair of bone.
Claim 10
Dependent Claim 41 words
The method of claim 1 wherein the cells are genetically engineered periosteal cells expressing BMP-7 in an amount effective to enhance the repair of osteochondral defects, comprising implanting the cells at the site where an osteochondral defect is to be repaired.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2003-06-20 2003-12-20 2004-06-20 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2007-06-20 2007-12-20 2008-06-20 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2011-06-20 2011-12-20 2012-06-20 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag